Brokerages Expect Intellia Therapeutics Inc (NTLA) to Announce -$0.59 Earnings Per Share
Equities research analysts forecast that Intellia Therapeutics Inc (NASDAQ:NTLA) will post ($0.59) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Intellia Therapeutics’ earnings. The lowest EPS estimate is ($0.78) and the highest is ($0.48). Intellia Therapeutics posted earnings per share of ($0.51) in the same quarter last year, which suggests a negative year over year growth rate of 15.7%. The company is expected to issue its next earnings results on Tuesday, May 7th.
According to Zacks, analysts expect that Intellia Therapeutics will report full-year earnings of ($2.59) per share for the current financial year, with EPS estimates ranging from ($3.35) to ($1.84). For the next year, analysts expect that the firm will report earnings of ($2.62) per share, with EPS estimates ranging from ($3.81) to ($1.68). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Intellia Therapeutics.
Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Wednesday, February 27th. The company reported ($0.43) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.12. The business had revenue of $7.90 million for the quarter, compared to analysts’ expectations of $9.92 million. Intellia Therapeutics had a negative net margin of 280.42% and a negative return on equity of 30.59%. The firm’s revenue for the quarter was up 17.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.61) earnings per share.
Intellia Therapeutics stock traded down $0.06 during trading hours on Tuesday, hitting $16.15. 484,192 shares of the stock were exchanged, compared to its average volume of 434,313. The stock has a market capitalization of $734.49 million, a price-to-earnings ratio of -8.16 and a beta of 2.95. Intellia Therapeutics has a 12 month low of $11.03 and a 12 month high of $32.95.
In other news, EVP Andrew Schiermeier acquired 7,500 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was bought at an average price of $15.72 per share, with a total value of $117,900.00. Following the transaction, the executive vice president now directly owns 3,250 shares in the company, valued at approximately $51,090. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 4.10% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of NTLA. Ontario Teachers Pension Plan Board acquired a new stake in shares of Intellia Therapeutics during the 4th quarter worth about $22,659,000. Rehmann Capital Advisory Group acquired a new stake in shares of Intellia Therapeutics during the 3rd quarter worth about $14,409,000. Vanguard Group Inc lifted its stake in shares of Intellia Therapeutics by 12.2% during the 3rd quarter. Vanguard Group Inc now owns 2,653,165 shares of the company’s stock worth $75,934,000 after buying an additional 287,682 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Intellia Therapeutics by 12.2% during the 3rd quarter. Vanguard Group Inc. now owns 2,653,165 shares of the company’s stock worth $75,934,000 after buying an additional 287,682 shares during the last quarter. Finally, Deutsche Bank AG lifted its stake in shares of Intellia Therapeutics by 75.5% during the 4th quarter. Deutsche Bank AG now owns 635,956 shares of the company’s stock worth $8,680,000 after buying an additional 273,501 shares during the last quarter. Institutional investors own 69.64% of the company’s stock.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
Further Reading: Ex-Dividend
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.